BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 24604058)

  • 21. Concepts for Immunotherapies in Gliomas.
    Platten M; Reardon DA
    Semin Neurol; 2018 Feb; 38(1):62-72. PubMed ID: 29548053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-Based Immunotherapy of Gliomas.
    Everson RG; Antonios JP; Liau LM
    Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exosomes as drug delivery systems in glioma immunotherapy.
    Hao X; Wang S; Wang L; Li J; Li Y; Liu J
    J Nanobiotechnology; 2024 Jun; 22(1):340. PubMed ID: 38890722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment.
    Xu Y; Zhang H; Sun Q; Geng R; Yuan F; Liu B; Chen Q
    Front Immunol; 2021; 12():730289. PubMed ID: 34659216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for human glioma: innovative approaches and recent results.
    Hussain SF; Heimberger AB
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
    Kwok D; Okada H
    J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A blood-brain barrier- and blood-brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy.
    Tang L; Zhang R; Wang Y; Liu M; Hu D; Wang Y; Yang L
    J Control Release; 2024 May; 369():642-657. PubMed ID: 38575072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell-based active specific immunotherapy for malignant glioma.
    Parajuli P; Mathupala S; Mittal S; Sloan AE
    Expert Opin Biol Ther; 2007 Apr; 7(4):439-48. PubMed ID: 17373896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principles of immunotherapy.
    Liebelt BD; Finocchiaro G; Heimberger AB
    Handb Clin Neurol; 2016; 134():163-81. PubMed ID: 26948354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concepts in glioma immunotherapy.
    Platten M; Bunse L; Wick W; Bunse T
    Cancer Immunol Immunother; 2016 Oct; 65(10):1269-75. PubMed ID: 27460064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
    Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
    J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
    Pollack IF; Okada H; Chambers WH
    Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y; Black KL; Yu JS
    Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Difficulties and prospects in the immunotherapy of gliomas].
    Mangel L; Najbauer J; Kajtár B; Pongrácz EJ
    Magy Onkol; 2019 Sep; 63(3):217-223. PubMed ID: 31533142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide-based immunotherapeutic approaches to glioma: a review.
    Yamanaka R; Itoh K
    Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell vaccines and immunity in glioma patients.
    Wheeler CJ; Black KL
    Front Biosci; 2005 Sep; 10():2861-81. PubMed ID: 15970541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for glioma: Current management and future application.
    Xu S; Tang L; Li X; Fan F; Liu Z
    Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.